Loading...
•
Jun 30, 2020
Boston Scientific Q2 2020 Earnings Report
Boston Scientific's financial performance declined due to the impact of the COVID-19 pandemic, but the business showed signs of recovery during the quarter.
Key Takeaways
Boston Scientific reported a decline in sales and a GAAP loss for the second quarter of 2020, primarily due to the impact of the COVID-19 pandemic. However, the company saw business recovering over the course of the quarter and achieved adjusted earnings per share of $0.08.
Second quarter sales declined in each reportable segment compared to the prior year period.
Second quarter regional sales also declined compared to the prior year period.
Received FDA approval for the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device.
Launched a multi-year program to combat racism, inequity and injustice, including $3.5 million in philanthropic commitments.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The company did not provide second quarter sales and EPS guidance due to ongoing uncertainty associated with the scope and duration of the COVID-19 pandemic.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...